[1] 韩春颖, 门文婷, 刘珊珊, 等. 妊娠合并卵巢恶性肿瘤的研究进展[J]. 中国现代医学杂志, 2019, 29(14): 54. doi: 10.3969/j.issn.1005-8982.2019.14.011
[2] FRUSCIO R, DE HAAN J, VAN CALSTEREN K, et al. Ovarian cancer in pregnancy[J]. Best Pract Res Clin Obstet Gynaecol, 2017, 41(1): 108.
[3] 陈小炎, 刘也夫. 血清肿瘤标志物在原发性肝癌诊断中的研究进展[J]. 现代肿瘤医学, 2019, 27(9): 168.
[4] 李小亚, 高炯, 谢洋, 等. 高频多普勒超声检查联合血清肿瘤标志物对卵巢良、恶性肿瘤诊断价值研究[J]. 空军医学杂志, 2018, 34(5): 323.
[5] SHIN KH, KIM HH, KWON BS, et al. Clinical usefulness of cancer antigen(CA) 125, human epididymis 4, and CA72-4 levels and risk of ovarian malignancy algorithm values for diagnosing ovarian tumors in Korean patients with and without endometriosis[J]. Ann Lab Med, 2020, 40(1): 40. doi: 10.3343/alm.2020.40.1.40
[6] 汤俊, 黄春锦, 陈玺. 老年结直肠癌患者血清内CEA、AFP、CA50、CA199和CA724的表达及意义[J]. 实用癌症杂志, 2019, 34(3): 53.
[7] 唐海峰, 李贤, 刘蓓. 人附睾上皮分泌蛋白4在卵巢癌检测中的作用评估[J]. 中华生物医学工程杂志, 2018, 24(2): 135. doi: 10.3760/cma.j.issn.1674-1927.2018.02.012
[8] MICHIELSEN K, DRESEN R, VANSLEMBROUCK R, et al. Diagnostic value of whole body diffusion weighted MRI compared to computed tomography for pre-operaIive assessment of patients suspected for ovarian cancer[J]. Eur J Cancer, 2017, 83(1): 88.
[9] 中国抗癌协会妇科肿瘤专业委员会. 卵巢恶性肿瘤诊断与治疗指南(第四版)[J]. 中国实用妇科与产科杂志, 2018, 34(11): 1227.
[10] SUH DH, CHANG SJ, SONG T, et al. Practice guidelines for management of ovarian cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement[J]. J Gynecol Oncol, 2018, 29(4): e56. doi: 10.3802/jgo.2018.29.e56
[11] 胡惟恺, 丁新, 阴赪宏. 妊娠合并卵巢癌诊疗进展[J]. 中国医刊, 2020, 55(1): 14.
[12] 张爱红, 段元兰, 黄亚岚, 等. 高危妊娠合并卵巢癌患者应用米非司酮联合贝伐珠单抗的疗效分析[J]. 肿瘤药学, 2018, 8(2): 236. doi: 10.3969/j.issn.2095-1264.2018.02.25
[13] MOMENIMOVAHED Z, TIZNOBAIK A, TAHERI S, et al. Ovarian cancer in the world: epidemiology and risk factors[J]. Int J Womens Health, 2019, 11(1): 287.
[14] 黄富灵, 韩磊, 蒋红梅. 妊娠合并妇科恶性肿瘤的临床管理进展[J]. 医学综述, 2019, 25(19): 3828. doi: 10.3969/j.issn.1006-2084.2019.19.017
[15] 冯敏芝, 伍诗媚, 李建聪. 超声在妊娠合并卵巢肿瘤患者的诊断价值[J]. 分子影像学杂志, 2019, 42(4): 439.
[16] 张彩虹, 古航. 妊娠合并妇科恶性肿瘤分娩时机及分娩方式的选择[J]. 中国实用妇科与产科杂志, 2018, 34(10): 23.
[17] 郭融, 蔡钰峰, 王茂淮, 等. 血清学CA724, CA125检测联合ROMA值在卵巢癌诊断中的价值[J]. 国际检验医学杂志, 2020, 41(2): 168. doi: 10.3969/j.issn.1673-4130.2020.02.010
[18] YU J, ZHENG W. An alternative method for screening gastric cancer based on serum levels of CEA, CA19-9, and CA72-4[J]. J Gastrointest Cancer, 2018, 49(1): 57. doi: 10.1007/s12029-016-9912-7
[19] MARIAMPILLAI AI, CRUZ JPD, SUH J, et al. Cancer antigen 72-4 for the monitoring of advanced tumors of the gastrointestinal tract, lung, breast and ovaries[J]. Anticancer Res, 2017, 37(7): 3649.
[20] 胡薇, 徐鸿绪, 陈启斌, 等. 血清CA724、CYFRA21-1及PIVKA-Ⅱ诊断卵巢癌价值[J]. 中国计划生育学杂志, 2019, 27(2): 230.
[21] DOCHEZ V, CAILLON H, VAUCEL E, et al. Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review[J]. J Ovarian Res, 2019, 12(1): 28. doi: 10.1186/s13048-019-0503-7
[22] 高全霞, 杨贵岚, 张立欣, 等. CA19-9, HE4, CEA联合超声造影诊断卵巢癌的价值[J]. 中国妇幼保健, 2018, 33(10): 2369.
[23] 李玲, 周一波, 吴美艳, 等. 卵巢肿瘤超声造影血流特征与肿瘤恶性程度的相关性研究[J]. 中华内分泌外科杂志, 2018, 12(2): 150. doi: 10.3760/cma.j.issn.1674-6090.2018.02.015
[24] WANG M, FENG HL, LIU YQ, et al. Angiogenesis research in mouse mammary cancer based on contrast-enhanced ultrasonography: exploratory study[J]. Acad Radiol, 2018, 25(7): 889. doi: 10.1016/j.acra.2017.12.004
[25] 胡海平, 赵海娜, 马步云, 等. 常规超声及超声造影对甲状腺囊性乳头状癌的诊断价值[J]. 肿瘤预防与治疗, 2020, 33(2): 147.
[26] 杨阿芳. 卵巢癌超声造影参数与血管新生, 癌细胞生长的相关性研究[J]. 海南医学院学报, 2018, 24(2): 273.
[27] 时小青, 吴秋花. 卵巢癌超声造影参数与血管新生的相关性研究[J]. 实用癌症杂志, 2019, 34(8): 151.